Background and Importance {#s1}
=========================

High-frequency deep brain stimulation of the subthalamic nucleus deep brain stimulation (STN-DBS) improves the primary motor symptoms of Parkinson\'s disease (PD). However, this stimulation at a fixed high frequency does not improve or may even exacerbate the axial symptoms and signs (such as problems with gait, speech, or swallowing) that often emerge over the long-term course of treatment and disease ([@B1]). Recent evidence suggests that STN-DBS at a fixed lower frequency (\< 100 Hz) could improve speech and gait ([@B2], [@B3]). However, the tremor might worsen significantly with fixed low-frequency stimulation ([@B4]). Here, we present a case of PD that was treated effectively by applying variable-frequency stimulation (VFS) containing only a combination of high frequencies. A written informed consent was obtained from the patient, both for participation and for the academic publication of this case report.

Clinical Presentation {#s2}
=====================

The case involved a female patient who developed severe speech problems after long-term high-frequency STN-DBS for PD. In 1998, at the age of 23, she was diagnosed with PD. In 2002, she received bilateral STN-DBS (Kinetra 7428, Medtronic, Minneapolis, MN, USA) for severe medication-resistant tremor. The position of the most ventral DBS contacts was shown in [Figure 1](#F1){ref-type="fig"}. After STN-DBS onset, she first decided to reduce the dosage of anti-Parkinson medications and then stopped taking the drugs altogether. One year after surgery, she was medication-free and gave birth to a baby. She received subsequent battery replacements in 2006, 2009, and 2012. For over a decade, her motor symptoms responded well to DBS at 170 Hz. However, from April 2015 onwards, she experienced increasing difficulties in standing up from a sitting position and with her speech/phonation. The adjustments made to her DBS parameters and medication were not helpful. Post-operative magnetic resonance imaging confirmed that the DBS leads were correctly located in the STN and had not migrated. In December 2015, we replaced the DBS battery of the patient with a rechargeable battery (G102, PINS, Beijing, China). As stimulation at a fixed low frequency might exacerbate the tremor evident in this patient, we explored the value of VFS in treating her motor symptoms, which was made possible by the battery change ([@B5]). The same parameters were selected: right, 1-2-3-Case+, 3.55 V, 100 us, 170 Hz; left, 6-7-C+, 3.35 V, 90 us, 170 Hz.

![The most ventral DBS contacts location.](fneur-10-00379-g0001){#F1}

We evaluated the effects of three different sets of VFS on the patient\'s motor function. Initially, the frequencies used in each set were randomly chosen from a group of six frequencies (170, 160, 145, 125, 90, 60 Hz). Ten minutes after the delivery of each VFS stimulus, a speech therapist assessed the patient\'s vocal and speech performance by taking into account (a) the quality of articulation when she pronounced her name, date of birth, and an 8-syllable Chinese tongue-twister; (b) the maximum phonation time when pronouncing /ah/; and (c) the loudness of the sound of her voice, as indicated by the maximum sound pressure level while the patient produced a loud, clear sound for as long as possible (UT-352, Uni-Trend Technology, Ltd., Shenzhen, China). A movement disorder specialist also performed follow-up motor assessments using established clinical instruments. Other stimulation parameters (i.e., the contacts, amplitude, pulse width) were kept the same while frequencies were varied across VFS sets.

The first set of VFS parameters used contained two low-frequency components (90 and 60 Hz). Following the application of this set, the patient could no longer speak, and her tremor immediately recurred. We therefore excluded these low frequencies from further consideration. Next, we evaluated our second set, involving 160 Hz (10 s), 145 Hz (15 s), 125 Hz (10 s), 145 Hz (15 s), and 160 Hz (10 s). Note that 145 and 160 Hz were used twice within this set as a 1-min loop. The second VFS set was found to alleviate her bradykinesia, muscle rigidity, and axial symptoms on day one and 1 month follow-ups ([Table 1](#T1){ref-type="table"}). We then evaluated our third set involving 160, 155, 145, 130, and 125 Hz (10 s) at the 1 month follow-up. Similar to the second parameter set, the third VFS set improved the patient\'s bradykinesia, rigidity, and axial symptoms at the 3 months follow-up, as compared to no STN-DBS treatment or fixed high-frequency STN-DBS ([Table 1](#T1){ref-type="table"}). Thus, the two VFS sets were both effective for primary motor symptoms, but the third set improved the axial symptoms better than the second set.

###### 

Patient\'s motor symptom severity before and after variable-frequency stimulation.[^\*^](#TN1){ref-type="table-fn"}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Clinical variable**   **Off**              **HFS**                **2nd VFS (1-day follow-up)**   **2nd VFS (1-month follow-up)**   **3rd VFS (3-months follow-up)**
  ----------------------- -------------------- ---------------------- ------------------------------- --------------------------------- ----------------------------------
  Total                   90                   50                     45                              39                                35

  Tremor                  10                   6                      6                               5                                 5

  Rigidity                20                   8                      8                               2                                 2

  Bradykinesia            40                   24                     22                              22                                22

  Axial symptoms          20                   12                     9                               10                                6

  Speech                  4                    3                      3                               2                                 2

  Gait                    4                    2                      2                               2                                 1

  Posture                 4                    2                      1                               2                                 1

  Postural stability      4                    2                      2                               2                                 2

  Arise from chair        4                    3                      1                               2                                 0

  TUG (sec)               Unable to complete   10                     12                              10                                11

  Hoehn-Yahr Stage        5                    3                      3                               3                                 3

  GFQ                     NA                   36                     32                              32                                32

  Voice loudness          NA                   Max duration = 2.2,\   Max duration = 3.3,\            Max duration = 2.3,\              Max duration = 3.4,\
                                               max SPL = 89.0         max SPL = 98.1                  max SPL = 93.2                    max SPL = 97.6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Motor symptom severity was assessed by using the Unified Parkinson\'s Disease Rating Scale (UPDRS)-III, unless indicated otherwise. Off, no STN-DBS; HFS, 170 Hz; HFS, High Frequency Stimulation; LFS, Low Frequency Stimulation; TUG, Time Up and Go test; GFQ, Gait and Falls Questionnaire; SPL, Sound Pressure Level; NA, Not Available*.

Discussion and Conclusion {#s3}
=========================

In PD, axial symptoms, and signs involving problems with gait and speech are common, especially in advanced stages of the disease. For the affected, these symptoms often lead to functional impairment and a lower perceived quality of life. It is known that STN-DBS treatment using fixed high frequencies, while being effective in controlling the primary motor symptoms of PD, may induce or aggravate speech and voice dysfunctions ([@B1]). VFS containing low frequencies has been reported to relieve severe subthalamic stimulation-induced dysarthria, yet this stimulation has also been found to worsen the tremor ([@B2]). Our results confirm the latter observation by showing that VFS containing low frequencies alone worsened the tremor in the present case. By contrast, VFS containing several higher frequencies improved both the tremor and axial signs including speech problems in our patient.

This case report describes the application of new paradigms for DBS programming, made possible by technological advances. Unfortunately, for the different sets of VFS tested here, the stimulation amplitude and pulse width could not be varied. One possible explanation for the scarce efficacy of the first VFS set (containing high and low frequencies) could be that low frequencies typically require a higher stimulation intensity to be at least as effective as the high frequencies. The differences between the two high-frequency sets of VFS implied that switching more frequently seems to be advantageous. Although assessment is usually done 30 min after stimulation, we assessed her speech after 10 min because this patient is very sensitive and reached a stable clinical effect quickly. Furthermore, the data is comparable as the conditioning followed the same protocol.

These observations indicate that VFS may be of clinical utility in the management of advanced PD. Future large-scale studies are needed to confirm our findings and elucidate the mechanism of VFS, and to establish whether it alleviates the detrimental effect of HFS, DBS or has a beneficial effect.
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